Cargando...
OP17. Measuring and modifying Temozolomide delivery in brain tumours
INTRODUCTION: Malignant brain tumours constitute a fatal diagnosis with 5-year survival rates of less than 5%. Temozolomide (TMZ) is the central chemotherapy agent used in the treatment of malignant brain tumours; however, despite aggressive treatment approaches outcomes are still poor with many pat...
Guardado en:
| Publicado en: | Neuro Oncol |
|---|---|
| Autores principales: | , , , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
Oxford University Press
2017
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5358586/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/now292.016 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|